Pharmaceuticals, Biotechnology and Life Sciences
WOBURN, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) — Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the…
– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff…
SAN DIEGO, Jan. 31, 2022 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a…
Daix (France), Long Island City (New York, United States), January 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a…
Based on the global license agreement signed in April 2021, this first milestone triggers a €5 million payment from Veloxis…
Orphazyme A/SCompany announcementNo. 03/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, January 31, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or…
– Michelle Lock Joins Covis Pharma as Chief Operating Officer.- Also Announces Executive Leadership Transition with the Appointment of Sandy…
Picture1TORONTO, Jan. 31, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the “Company”),…
STRATHROY, Ontario, Jan. 31, 2022 (GLOBE NEWSWIRE) — Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE;…
TORONTO, Jan. 28, 2022 (GLOBE NEWSWIRE) — Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQX: MVMDF)…